Juvenile Arthritis

Top Story

EMA recommends approval of Humira biosimilar Imraldi

EMA recommends approval of Humira biosimilar Imraldi
June 23, 2017

The European Medicines Agency has recommended the approval of the Imraldi, making it the third anti-TNF biosimilar candidate to receive a positive opinion from the Committee for Medicinal Products for Human Use, the manufacturer announced.

Imraldi (SB5, Samsung Bioepis) is a biosimilar candidate referencing Humira (adalimumab, AbbVie), indicated for rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hydradentis suppurativa, Crohn’s disease in adults and children, ulcerative colitis and uveitis.

In the JournalsPerspective

AAHKS, ACR release guidelines for management of antirheumatic drugs for patients who undergo TKA, THA

June 19, 2017
The American College of Rheumatology has partnered with the American Association of Hip and Knee Surgeons to develop evidence-based guidelines for perioperative…

Subcutaneous abatacept now available for patients with JIA

June 9, 2017
Subcutaneous abatacept is now available for patients aged 2 years or older with moderately to severely active polyarticular juvenile idiopathic arthritis, according to a…
In the Journals

Researchers compare CCP profile of patients with JIA vs RA

April 26, 2017
Among patients with rheumatoid arthritis and patients with a polyarticular subtype of juvenile idiopathic arthritis, researchers at University College London compared…
CME

Pediatric Rheumatology: June 2015

Keck School of Medicine of USC and Pediatric Annals

Of all the areas of pediatric practice, none can seem more daunting or require a higher index of suspicion than…
More »
Video
Meeting News Coverage

VIDEO: Mamaras highlights CreakyJoints' patient advocacy

November 27, 2015
More »
Resource Centers
EULAR Annual Congress

EULAR Annual Congress

CME

Timing of Tourniquet Release in Total Knee Arthroplasty: July 2015

The authors conducted a meta-analysis to determine the optimal tourniquet application strategy in total knee…
More »

EMA recommends approval of Humira biosimilar Imraldi

June 23, 2017
The European Medicines Agency has recommended the approval of the Imraldi, making it the third anti-TNF biosimilar candidate to receive a positive…

In the JournalsPerspective

AAHKS, ACR release guidelines for management of antirheumatic drugs for patients who undergo TKA, THA

June 19, 2017
The American College of Rheumatology has partnered with the American Association of Hip and Knee Surgeons to develop evidence-based guidelines for…

Subcutaneous abatacept now available for patients with JIA

June 9, 2017
Subcutaneous abatacept is now available for patients aged 2 years or older with moderately to severely active polyarticular juvenile idiopathic…

In the Journals

Researchers compare CCP profile of patients with JIA vs RA

April 26, 2017
Among patients with rheumatoid arthritis and patients with a polyarticular subtype of juvenile idiopathic arthritis, researchers at University…

Biosimilars to rituximab, etanercept recommended for approval in Europe

April 21, 2017
The Committee for Medicinal Products for Human Use has recommended approval of biosimilars by Sandoz for rituximab and etanercept for the same…

In the Journals

Study: Published criteria to identify inactive JIA do not always overlap

April 20, 2017
Published criteria to identify inactive disease or low disease activity do not always identify the same patients, according to a recently published…

In the Journals

Higher rates of complications after THA found among patients with inflammatory arthritis

April 17, 2017
Patients with inflammatory arthritis who underwent total hip arthroplasty experienced higher rates of complications compared with patients who had…

In the Journals

Etanercept, adalimumab linked with increased infection risk vs methotrexate for JIA

April 4, 2017
Investigators found a slightly increased risk for serious infection among patients with juvenile idiopathic arthritis who took first-line etanercept…

European Commission approves adalimumab biosimilar for treatment of RA, PsA, AS, JIA

March 27, 2017
The European Commission has approved Amgevita, a biosimilar to adalimumab, for the treatment of moderate to severe rheumatoid arthritis, psoriatic…

In the Journals

Uveitis linked with reduced vision-related quality of life in adulthood for patients with JIA

March 7, 2017
A history of uveitis had a negative effect on vision-related quality of life in adulthood for patients with juvenile idiopathic arthritis, according…

More Headlines »
Advertisement
Advertisement